title: Preferential sensitivity of hematopoietic (HPs) and mesenchymal (MPs) progenitors to fludarabine suggests impaired bone marrow niche and HP mobilization.
authors.forename: M G
authors.initials: MG
authors.lastname: Berger
authors.forename: J
authors.initials: J
authors.lastname: Berger
authors.forename: C
authors.initials: C
authors.lastname: Richard
authors.forename: S
authors.initials: S
authors.lastname: Jeanpierre
authors.forename: F E
authors.initials: FE
authors.lastname: Nicolini
authors.forename: O
authors.initials: O
authors.lastname: Tournilhac
authors.forename: M
authors.initials: M
authors.lastname: Michallet
authors.forename: V
authors.initials: V
authors.lastname: Maguer-Satta
authors.forename: V M
authors.initials: VM
authors.lastname: Satta
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology*; D001853:Bone Marrow / Q000187:drug effects*; D002465:Cell Movement / Q000187:drug effects*; D002470:Cell Survival / Q000187:drug effects; D002478:Cells, Cultured; D003114:Colony-Forming Units Assay; D004730:Endothelium, Vascular / Q000166:cytology / Q000187:drug effects / Q000378:metabolism; D006412:Hematopoietic Stem Cells / Q000166:cytology / Q000187:drug effects*; D006801:Humans; D059630:Mesenchymal Stem Cells / Q000166:cytology / Q000187:drug effects*; D017154:Stromal Cells / Q000187:drug effects; D014740:Vidarabine / Q000031:analogs & derivatives* / Q000494:pharmacology
chemical_list: D000970:Antineoplastic Agents; D014740:Vidarabine; C024352:fludarabine